NCT02217813View on ClinicalTrials.gov

A Bioequivalence Study Comparing Two Different Tafamidis Formulations

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Healthy Volunteers

Interventions

DRUG

Tafamidis

20 mg of current commercial formulation

DRUG

Tafamidis

20 mg of new formulation

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY